Displaying 39 (all) recruiting clinical trials.
-
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will ... -
Phase 3 study evaluating AMG 757 Tarlatamab for patients with Small Cell Lung Cancer
This study is for patients with small cell lung cancer (SCLC). They want to see if a new treatment called tarlatamab (an immunotherapy that might ... -
A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
This is a study to see if a new medicine called epcoritamab (works by binding to CD3 and CD20 on cells, which brings T cells ...
-
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
This study is about patients who have recently been diagnosed with early-stage classical Hodgkin lymphoma (cHL). The researchers want to compare two treatment approaches: one ...
-
A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
This study is to see if a new medicine called AK112 can help patients with advanced non-squamous non-small cell lung cancer (NSCLC) that didn't ...
-
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
This study is testing if a new treatment works for patients with hepatocellular carcinoma (HCC) that's either very advanced or has spread to other ...
-
A Phase 3 Randomized Double-blind Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This research study is for people who are 12 years of age or older and weigh at least 40 kg, and who have had surgery ...
-
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is a large global study for people with a type of breast cancer called triple-negative breast cancer (TNBC). It's happening in many hospitals ...
-
A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
This study wants to find out if a new treatment called V940, when used with pembrolizumab, has fewer side effects and is more effective than ...